Tamarind Bio, Inc. provides AI infrastructure for biotech R&D, offering top computational biology tools to design and score proteins, peptides, and small molecules. Headquartered in San Francisco, California, the platform aims to accelerate discovery and research in the life sciences sector.
Subscribe to see Tamarind Bio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Tamarind Bio is a biotech company headquartered in United States. Its most recent funding round, Series A, raised $13.6M in February 2026. Xcout tracks 4 named people at Tamarind Bio, including Deniz Kavi (CEO).
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $13.6M | 3 named | |
| SEC Form D filing | $13.6M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Tamarind Bio's closest competitors — see the full list of competitors and alternatives →
Form Bio is a computational life sciences company headquartered in San Carlos, California, providing AI-driven software solutions for genetic medicines and multi-species genome engineering.
LatchBio is a biotechnology and healthcare technology company that provides computational infrastructure and data analysis platforms for life sciences. Headquartered in San Francisco, California, the company integrates biosecurity initiatives following the acquisition of TwentyTwo.
BioStack Platforms is a software development company headquartered in the United States, with locations mentioned in both San Francisco, CA, and New Haven, CT. Founded in 2025, it provides novel pre-clinical and medical datasets, along with RL environments for post-market surveillance.
AbInitio Bio is developing the first foundation models specifically for biomanufacturing. The company is headquartered in San Francisco.
Atomic AI is a biotechnology research company specializing in RNA drug discovery utilizing atomic precision. Headquartered in San Francisco, California, the company combines machine learning and biology to develop advanced therapeutics.
Convexia is a biotechnology research company headquartered in San Francisco, California, United States. It utilizes an end-to-end AI stack to quickly find and acquire early-stage drugs, replacing traditional manual diligence processes with fast execution.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.